

REFERENCE

- Adkins, J. N., Varnum, S. M., Auberry, K. J., Moore, R. J., Angell, N. H., Smith, R. D., Springer, D. L., and Pounds, J. G. 2002. Toward a human blood serum proteome: Analysis by multidimensional separation coupled with mass spectrometry. *Molecular & Cellular Proteomics*. 1: 947–955.
- Albert, P.R. 2012. Transcriptional regulation of the 5-HT1A receptor: implications for mental illness. *Phil Trans R Soc. B* 367: 2402–2415.
- American Psychiatric Association. 1994. *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition*. Washington, D.C.: American Psychiatric Association.
- American Psychiatric Association. 2000. Practice guideline for the treatment of patients with major depressive disorder (revision). *Am J Psychiatry*. Apr; 157 (4): 1-45.
- Anderson, N. L., and Anderson, N. G. 2002. Review: The human plasma proteome: History, character, and diagnostic prospects. *Molecular & Cellular Proteomics*. 1: 845–867.
- Angst, J., and Dobler-Mikola, A. 1984. Do the diagnostic criteria determine the sex ratio in depression?. *Journal of Affective Disorders*. 7: 189-198.
- Arnold, S.E., Xie, S.X., Leung, Y.Y., Wang, L.S., Kling, M.A., Han, X., Kim, E.J., Wolk, D.A., Bennett, D.A., Chen-Plotkin, A., Grossman, M., Hu, W., Lee, V.M., Mackin, R.S., Trojanowski, J.Q., Wilson, R.S., and Shaw, L.M. 2012. Plasma biomarkers of depressive symptoms in older adults. *Transl Psychiatry*. 2: e65. doi: 10.1038/tp.2011.63.
- Austin, M.P. 2010. Classification of mental health disorders in the perinatal period: future directions for DSM-V and ICD-11. *Arch Womens Ment Health*, University of New South Wales, Sydney, Australia. 13: 41–44.
- Bahk, Y.Y., Na, B.K., Cho, S.H., Kim, J.Y., Lim, K.J., and Kim, T.S. 2010. Proteomic Analysis of Haptoglobin and Amyloid A Protein Levels in Patients with Vivax Malaria. *J Parasitol*. 48(3): 203-211.
- Belmaker, R.H., and Agam, G. 2008. Mechanisms of Disease Major Depressive Disorder. *The new england journal of medicine*. 358: 55-68.

- Berk, M., Wadee, A.A., Kuschke, R.H., and O'Neill-Kerr, A. 1997. Acute phase proteins in major depression. *J Psychosom Res.* 43: 529-534.
- Bhatia, S.K., and Bhatia, S.C. 2007. Childhood and Adolescent Depression. *Am Fam Physician.* 75: 73-80, 83-4.
- Bortolozzi, A., Castañé, A., Semakova, J., Santana, N., Alvarado, G., Cortés, R., Ferrés-Coy, A., Fernández, G., Carmona M.C., Toth, M., Perales, J.C., Montefeltro, A., and Artigas, F. 2011 Selective siRNA-mediated suppression of 5-HT(1A) autoreceptors evokes strong anti-depressant-like effects. *Mol Psychiatry.* 17: 612–623.
- Boyle, S.H., Jackson, W.G., and Suarez, E.C. 2007. Hostility, anger, and depression predict increases in C3 over a 10-year period. *Brain Behav Immun.* 21: 816-823.
- Brewis, I.A., and Brennan, P. 2010. Proteomics technologies for the global identification and quantification of proteins. *Adv Protein Chem Struct Biol.* 80: 1-44.
- Carrasco, J.L., and Sandner, C. 2005. Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview. *Int J Clin Pract.* 59: 1428–1434.
- Cipriani, A., Brambilla P., Furukawa, T., Geddes, J., Gregis, M., Hotopf, M., Malvini, L. and Barbui, C. 2009. Fluoxetine versus other types of pharmacotherapy for depression. *Cochrane Database Syst Rev.* 4:CD004185.
- Cipriani, A., La, F., T., Furukawa, T.A., Signoretti, A., Nakagawa, A., Churchill, R., McGuire, H. and Barbui, C. 2010. Sertraline versus other antidepressive agents for depression. *Cochrane Database Syst Rev.* 4:CD006117.
- Cuijpers, P., van Straten, A., Schuurmans, J., van Oppen, P., Hollon, S.D., and Andersson, G. 2010. Review: Psychotherapy for chronic major depression and dysthymia a meta-analysis. *Clinical Psychology.* 30(1):51–62.
- Davalos, D., and Akassoglou, K. 2012. Fibrinogen as a key regulator of inflammation in disease. *Semin Immunopathol.* 34: 43-62.
- De Maat, S., Dekker, J., Schoevers, R. A., and de Jonghe, F. 2007. Relative efficacy of psychotherapy and combined therapy in the treatment of depression: A meta analysis. *European Psychiatry.* 22: 1–8.

- Dean, B. 2011. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. *Int J Neuropsychopharmacol.* 14: 997–1012.
- Descarries, L., and Riad, M. 2012. Effects of the antidepressant fluoxetine on the subcellular localization of 5-HT_{1A} receptors and SERT. *Philos Trans R Soc Lond B Biol Sci.* 367: 2416-2425.
- Dinarello, C.A. 2010. Anti-inflammatory Agents: Present and Future. *Cell.* 140: 935-950.
- Dowlatshahi, D., MacQueen, G.M., Wang, J.F., and Young, L.T. 1998. Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. *Lancet.* 352: 1754–1755.
- Duman, R.S., and Monteggia, L.M. 2006. A neurotrophic model for stress-related mood disorders. *Biol Psychiatry.* 59: 1116–1127. doi: 10.1016/j.biopsych.2006.02.013.
- Eaton, W.W., Anthony, J.C., Gallo, J., Cai, G., Tien, A., Romanoski, A., Lyketsos, C. and Chen, L.S. 1997. Natural history of diagnostic interview schedule/DSM-IV major depression. The Baltimore epidemiologic catchment area follow-up. *Arch Gen Psychiatry.* 54: 993–999.
- Erdem, M., Celik, C., Cayci, T., Ozdemir, B., Kurt, Y.G., Akgul, E.O, Yaman, H., Balikci, A., and Uzun, O. 2011. Serum haptoglobin levels in patients with melancholic and nonmelancholic major depression. *Progress in Neuro-Psychopharmacology and Biological Psychiatry.* 35(4): 944–947
- Esteve, G.F., Ixchel, H.G., Beatriz, C., Carlos, C.P., Jorge, E.H.A., Patricia M.M., David, C., Sandra, H., Alma, G., Mariana, Y.C.G., Rubén, A. R., and Joan, G.O. 2010. The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder. *Journal of Affective Disorders.* 127(1): 343-351.
- Fernie, A.R., Trethewey, R.N., Krotzky, A.J. and Willmitzer, L. 2004. Metabolite profiling: from diagnostics to systems biology. *Nat Rev Mol Cell Biol,* 5: 763-769.

- Fitzgerald, J.A. Major depressive disorder. 2012.
<http://www.minddisorders.com/Kau-Nu/Major-depressive-disorder.html>.
Encyclopedia of mental disorder. (accessed 29/12/2012).
- Fleck, M.P., and Horwath, E. 2005. Pharmacologic Management of Difficult-to-Treat Depression in Clinical Practice. *Psychiatr Serv.* 56: 1005–11
- Friedman, M.A., Detweiler-Bedell, J.B., Leventhal, H.E., Horne, R., Keitner, G.I., and Miller, I.W. 2004. Combined psychotherapy and pharmacotherapy for the treatment of major depressive disorder. *Clinical Psychology Science and Practice.* 11: 47–68.
- Gartlehner, G., Hansen, R.A., Thieda, P., DeVeaugh-Geiss, A.M., Gaynes, B.N., Krebs, E.E., Lux, L.J., Morgan, L.C., Shumate, J.A., Monroe, L.G., and Lohr, K.N. 2007. Review: Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression. *Comparative Effectiveness.* No 7. 1-167
- Gaynes, B.N, Rush, A.J, and Trivedi, M.H. 2007. Major depression symptoms in primary care and psychiatric care settings: a cross-sectional analysis. *Ann Fam Med.* 5: 126–134.
- Gopinath, S, Katon, W.J, Russo, J.E, and Ludman, E.J. 2007. Clinical factors associated with relapse in primary care patients with chronic or recurrent depression. *J Affect Disord.* 101: 57–63.
- Görg, A., Walter Weiss, W., Michael J., and Dunn, M.J. 2004. Current two-dimensional electrophoresis technology for proteomics. *Proteomics.* 4: 3665–3685.
- Gravel, P., Golaz, O., Walzer, C., Hochstrasser, D. F., Turler, H., and Balant, L. P. 1994. Analysis of glycoproteins separated by two-dimensional gel electrophoresis using lectin blotting revealed by chemiluminescence. *Anal. Biochem.* 221: 66–71.
- Gravel, P., Walzer, C., Aubry, C., Balant, L. P., Yersin, B., Hochstrasser, D. F., and Guimon, J. 1996. New alterations of serum glycoproteins in alcoholic and cirrhotic patients revealed by high resolution two-dimensional gel electrophoresis. *Biochem. Biophys. Res. Commun.* 220: 78–85.

- Hackett, M.L., Anderson, C.S., and House, A.O. 2004. Reviews: Interventions for treating depression after stroke. *Cochrane Database of Systematic*. 2.
- Hamilton, M: 1960. A rating scale for depression, *Journal of Neurology, Neurosurgery, and Psychiatry* 23: 56-62.
- Holmans, P., Weissman, M.M., Zubenko, G.S., Scheftner, W.A., Crowe, R.R., Depaulo, J.R.Jr., Knowles, J.A., Zubenko, W.N., Murphy-Eberenz, K., Marta, D.H., Boutelle, S., McInnis, M.G., Adams, P., Gladis, M., Steele, J., Miller, E.B., Potash, J.B., Mackinnon, D.F., and Levinson, D.F. 2007. Genetics of recurrent early-onset major depression (GenRED): final genomescan report. *Am J Psychiatry*. 164: 248-58.
- http://www.hopkinsmedicine.org/healthlibrary/conditions/mental_health_disorders/overview_of_mood_disorders_85_P00759/. Overview of Mood Disorders. (accessed 30/12/2012).
- Huang, Y., Qiao, F., Atkinson, C., Holers, V.M., and Tomlinson, S. 2008. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. *J Immunol*. 181: 8068-8076.
- Irie, F., Masaki, K.H., Petrovitch, H., Abbott, R.D., Ross, G.W., and Taaffe, D.R. 2008. Apolipoprotein E epsilon4 allele genotype and the effect of depressive symptoms on the risk of dementia in men: The Honolulu-Asia Aging Study. *Arch Gen Psychiatry*. 65(8): 906–12.
- Itzhaki, R.F., and Gill, D.M. 1964. A micro-biuret method for estimating proteins. *Anal Biochem*. Dec; 9: 401-10.
- Janciauskiene, S.M., Bals, R., Koczulla, R., Vogelmeier, C., Köhnlein, T., and Welte, T. 2011. The discovery of α 1-antitrypsin and its role in health and disease. *Respir Med*. 105: 1129-1139.
- Joyce, P.R., Hawes, C.R., Mulder, R.T., Sellman, J.D., Wilson, D.A., and Boswell, D.R. 1992. Elevated levels of acute phase plasma proteins in major depression. *Biol Psychiatry*. 32: 1035-1041.
- Judd, L.L., Akiskal, H.S., Maser, J.D., Zeller, P.J., Endicott, J., Coryell, W., Paulus, M.P., Kunovac, J.L., Leon, A.C., Mueller, T.I., Rice, J.A., and Keller, M.B. 1998. A prospective 12-year study of subsyndromal and syndromal depressive

- symptoms in unipolar major depressive disorders. *Arch Gen Psychiatry*. 55: 694–700.
- Karasu, T.B., Gelenberg, A., Merriam, A., and Wang, P. 2000. Practice Guideline for the Treatment of Patients With Major Depressive Disorder (Second Edition). *Am J Psychiatry*. 157(4): 1–45.
- Kemp, A.H., Gordon, E., Rush, J., and Williams, L. M. 2008. Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. *CNS Spectr*. 13(12): 1066-1086
- Kendler, K.S., Gardner, C.O., and Prescott, C.A. 2000. Clinical characteristics of major depression that predict risk of depression in relatives. *Arch Gen Psychiatry*. 56: 322-7.
- Kessler, R.C, Chiu, W.T, Demler, O., and Walters, E.E. 2005. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*. 62: 617–627.
- Kingsmore, S.F. 2006. Multiplexed protein measurement: technologies and applications of protein and antibody arrays. *Nat Rev Drug Discov*. 5(4): 310-320.
- Kopf, D., Westphal, S., Luley, C., Ritter, S., Gilles, M., Weber-Hamann, B., Lederbogen, F., Lehnert, H., Henn, F., Heuser, I., and Deuschle, M. 2004. Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment. *J Psychopharmacology*. 24: 527-531.
- Kovacs, M., Feinberg, T.L., and Crouse-Novak, M. 1984. Depressive disorders in childhood. II. A longitudinal study of the risk for a subsequent major depression. *Arch Gen Psychiatry*. 41: 643-649.
- Leuchter, A.F., Cook, I.A., Hamilton, S.P., Narr, K.L., Toga, A., Hunter, A.M., Faull, K., Whitelegge, J., Andrews, A.M., Loo, J., Way, B., Nelson, S.F., Horvath, S., and Lebowitz, B.D. 2010. Biomarkers to Predict Antidepressant Response. *Curr Psychiatry Rep*. 12(6): 553–562.

- Liang, Y., and Richelson, E. 2008. Triple Reuptake Inhibitors: Next-Generation Antidepressants. *Primary Psychiatry*. 15(4): 50-56
- Llano, D.A, Devanarayan, V., and Simon, A.J. 2012 Evaluation of Plasma Proteomic Data for Alzheimer Disease State Classification and for the Prediction of Progression From Mild Cognitive Impairment to Alzheimer Disease. *Alzheimer Dis Assoc Disord*. doi: 10.1097/WAD.0b013e31826d597a
- López, J.L. 2006. Two-dimensional electrophoresis in proteome expression analysis. *J Chromatogr B Analyt Technol Biomed Life Sci*. 849: 190-202.
- Lowther, S., Katona, C.L.E., Crompton, M.R., and Horton, R.W. 1997. Brain [3H]cAMP binding sites are unaltered in depressed suicides, but decreased by antidepressants. *Brain Res*. 758: 223–228.
- Lumley, J., Austin, M.P., and Mitchell, C. 2004. Review: Intervening to reduce depression after birth: A systematic review of the randomized trials. *International Journal of Technology Assessment in Health Care*. 20: 128–144.
- Maes, M. 1995. Review: Evidence for an immune response in major depression: a review and hypothesis. *Prog Neuropsychopharmacol Biol Psychiatry*. 19: 11–38.
- Marsden, W.N. 2012. Synaptic plasticity in depression: Molecular, cellular and functional correlates. *Prog Neuropsychopharmacol Biol Psychiatry*. doi:pii: S0278-5846(12)00323-5.
- Michels, A., Multhammer, M., Zintl, M., Mendoza, M.C., and Klünemann, H.H. 2012. Association of apolipoprotein E ε4 (ApoE ε4) homozygosity with psychiatric behavioral symptoms. *J Alzheimers Dis*. 28: 25-32.
- Ministry of Health Malaysia, 2007. Management of Major Depressive Disorder. Clinical Practice Guidelines.
- Mohr, D.C., and Goodkin, D.E. 1999. Review: Treatment of depression in multiple sclerosis: review and meta-analysis. *Clinical Psychology: Science and Practice*. 6: 1–9.
- Muller, N., Myint, A.M., and Schwarz, M.J. 2011. Inflammatory biomarkers and depression. *Neurotox Res*. 19: 308–318.
- Murphy, D., and Stephen, S. 2000. Darwin in the Madhouse: Evolutionary Psychology and the Classification of Mental Disorders, In Peter Carruthers

- and Andrew Chamberlain (eds), *Evolution and the Human Mind: Modularity, Language, and Meta-Cognition*, Cambridge University Press. pp. 62-92.
- Natale, M., Maresca, B., Abrescia, P., and Bucci, E.M. 2011. Image Analysis Workflow for 2-D Electrophoresis Gels Based on ImageJ. *Proteomics Insights*. 4: 37–49.
- Neuhoff, V., Arold, N., Taube, D., and Ehrhardt, W. 1988. Improved staining of proteins in polyacrylamide gels including isoelectric focusing gels with clear background at nanogram sensitivity using Coomassie Brilliant Blue G-250 and R-250. *Electrophoresis*. 9(6): 255–262.
- Nierenberg, A.A., Keefe, B.R., Leslie, V.C., Alpert, J.E. Pava, J.A., Worthington, J.J., Rosenbaum, J.F., and Fava, M. 1999. Residual symptoms in depressed patients who acutely to fluoxetine. *J. Clin.Psychiatry*. 60: 221–225.
- Nutt, D.J., Baldwin, D.S., Clayton, A.H., Elgie, R., Lecrubier, Y., Montejo, A.L., Papakostas, G.I., Souery, D., Trivedi, M.H., and Tylee, A. 2006. Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment. *J Clin Psychiatry* 67 Suppl. 6: 46-49.
- Odagaki, Y., Garcia-Sevilla, J.A., Huguelet, P., La Harpe, R., Koyama, T., and Guimon, J. 2001. Cyclic AMP-mediated signaling components are upregulated in the prefrontal cortex of depressed suicide victims. *Brain Res*. 898: 224–231.
- Olivier, J.D.A., Blom, T., Arentsen, T. and Homberg, J.R. 2010. Review: The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents. *Prog Neuro-Psychopharmacol Biol Psychiatry*. doi: 10.1016/j.pnpbp.09.013.
- Pampanolla, S., Bollini, P., Tibaldi, G., Kupelnick, B., and Munizza, C. 2004. Combined pharmacotherapy and psychological treatment for depression; a systematic review. *Archives of General Psychiatry*. 61: 714–719.
- Pan, B.X., Vautier, F., Ito, W., Bolshakov, V.Y., and Morozov, A. 2008. Enhanced Cortico-Amygdala Efficacy and Suppressed Fear in Absence of Rap1. *J Neurosci*. 28: 2089 –2098.
- Papakostas, G.I., Shelton, R.C., Kinrys, G., Henry, M.E., Bakow, B.R., Lipkin, S.H., Pi, B., Thurmond, L., and Bilello, J.A. 2011. Assessment of a multi-assay,

- serum-based biological diagnostic test for major depressive disorder: a Pilot and Replication Study. *Mol Psychiatry*. doi: 10.1038/mp.2011.166.
- Perez, J., and Tardito, D. 2001. Implications of the cAMP signaling pathway in psychiatric disorders: a systematic review of the evidence. *CNS Spectrums*. 4: 294–305.
- Perez, J., Tardito, D., Mori, S., Racagni, G., Smeraldi, E., and Zanardi, R. 2000. Abnormalities of cAMP signaling in affective disorders: implications for pathophysiology and treatment. *Bipolar Disorders*. 2: 27–36.
- Perez, J., Tardito, D., Mori, S., Racagni, G., Smeraldi, E., and Zanardi, R.. 2000. Altered Rap1 endogenous phosphorylation and levels in platelets from patients with bipolar disorder. *J Psychiatric Res*. 34: 99–104.
- Perez, J., Tardito, D., Racagni, G., Smeraldi, E., and Zanardi, R. 2001. Protein kinase A and Rap1 levels in platelets of untreated patients with major depression. *Mol Psychiatry*. 6: 44–49.
- Porcelli, S., Drago, A., Fabbri, C. and Serretti, A. 2010. Mechanisms of antidepressant action: an integrated dopaminergic perspective. *Prog Neuropsychopharmacol Biol Psychiatry*. (in press).
- Quaye, I.K. 2008. Haptoglobin, inflammation and disease. *Trans R Soc Trop Med Hyg*. 102: 735-742.
- Ramaswamy, S., and Perou, C.M. 2003. DNA microarrays in breast cancer: the promise of personalized medicine. *Lancet* 361, 1576-1577.
- Richard, R., Desrosiers, E'.B., Marguerite, B., and Richard, B. 2007. Proteomic Analysis of Human Plasma Proteins by Two- Dimensional Gel Electrophoresis and by Antibody Arrays Following Depletion of High-Abundance Proteins. *Cell Biochem Biophys*.49:182–195.
- Richelson, E. 2003. Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. *J Clin Psychiatry*. 64 (13): 5-12.
- Rifai, N., and Gerszten, R.E. 2006. Biomarker discovery and validation. *Clin Chem*. 2006. 52(9): 1635-1637.
- Rifai, N., Gillette, M.A., and Carr, S.A. 2006. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. *Nat Biotechnol*. 24(8): 971-983.

- Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Stewart, J.W., Nierenberg, A.A., Thase, M.E., Ritz, L., Biggs, M.M., Warden, D., Luther, J.F., Shores-Wilson, K., Niederehe, G., and Fava, M. 2006. Bupropion-SR, sertraline or venlafaxineXR alter failure of SSRI's for depression. *New Engl. J. Med.* 354: 1231–1242. implications for clinical practice. *Am. J. Psychiatry.* 163: 28–40.
- Sadeghi, M., Roohafza, H., Afshar, H., Rajabi, F., Ramzani, M., Shemirani, H., and Sarafzadeghan, N. 2011. Relationship between depression and apolipoproteins A and B: a case–control study. *Clinics (Sao Paulo)* 66: 113–117.
- Salim, S., Chugh, G., and Asghar, M. 2012. Inflammation in anxiety. *Adv Protein Chem Struct Biol.* 88: 1-25.
- Sarandol, A., Sarandol, E., Eker, S.S., Karaagac, E.U., Hizli, B.Z., Dirican, M., Kirli, S. 2006. Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder. *Prog Neuropsychopharmacol Biol Psychiatry.* 30: 1103-1180.
- Schiess, R., Wollscheid, B., and Aebersold, R. 2009. Targeted proteomic strategy for clinical biomarker discovery. *Mol Oncol.* 3: 33-44.
- Schneider, B., and Prvulovic, D. 2013. Novel biomarkers in major depression. *Curr Opin Psychiatry.* 26: 47-53.
- Sen, S., Duman, R., and Sanacoa, G. 2008. Serum BDNF, Depression and Anti-Depressant Medications: Meta-Analyses and Implications. *Biol Psychiatry.* 64(6): 527–532.
- Sen, S., Nesse, R.M., Stoltenberg, S.F., Li, S., Gleiberman, L., Chakravarti, A., Weder, A.B., and Burmeister, M. 2003. A BDNF coding variant is associated with the NEO personality inventory domain neuroticism, a risk factor for depression. *Neuropsychopharmacology.* 28(2): 397–401.
- Severus, W.E., Littman, A.B., and Stolln, A.L. 2001. Omega-3 fatty acids, homocysteine and the increased risk of cardiovascular mortality in major depressive disorder. *Harv Rev Psychiatry.* 9:280-293.
- Shirayama, Y., Chen, A.C., Nakagawa, S., Russell, D.S., and Duman, R.S. 2002. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. *J Neurosci.* 22(8): 3251–3261.

- Simon, G.G., and Claudine, B. 2005. Families and Mental Disorders From Burden to Empowerment: Families of Children with a Mental Disorder. University of Liverpool. Liverpool, UK: 127-159.
- Siuciak, J.A., Lewis, D.R., Wiegand, S.J., and Lindsay, R.M. 1997. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF) *Pharmacology, Biochemistry & Behavior*. 56(1): 131–137.
- Sklar, P., Gabriel, S.B., McInnis, M.G., Bennett, P., Lim, Y.M., Tsan, G., Schaffner, S., Kirov, G., Jones, I., Owen, M., Craddock, N., DePaulo, J.R., and Lande, E.S. 2002. Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus Brain-derived neurotrophic factor. *Mol Psychiatry*. 7(6): 579–593.
- Stahl, 2002. *Psicofarmacología esencial*. Ed. Ariel, Madrid.
- Steel, L.F., Haab, B.B., Hanash, S.M. 2005. Methods of comparative proteomic profiling for disease diagnostics. *J Chromatogr B Analyt Technol Biomed Life Sci*. 815: 275-284.
- Stengel, E., M.D., F.R.C.P. 1959. Classification of Mental Disorders. *Bull. Organ. Mond. Sante Bull. Wld Hlth Org*. 21: 601-663.
- Thase, M.E., Reynolds, C.F., Frank, E., Simons, A.D., McGeary, J., Fasiczka, A.L., Garamoni, G.G., and Kupfer, D.J. 1994. Do depressed men and women respond similarly to cognitive behavior therapy?. *American Journal of Psychiatry*. 151: 500-505.
- Trivedi, M.H., Rush, A.J., and Wisniewski, S.R. 2006. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. *Am J Psychiatry*. 63: 28-40.
- Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L., Norquist, G., Howland, R.H., Lebowitz, B.D., McGrath, P.J., Shores-Wilson, K., Biggs, M.M., Balasubramani, G.K., Fava, M. and STAR*D study team. 2006. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D.
- Waltereit, R., and Weller, M. 2003. Signaling from cAMP/PKA to MAPK and Synaptic Plasticity. *Mol Neurobiol*. 27: 99–106.

- Warden, D., Rush, A.J., Trivedi, M.H., Fava, M., and Wisniewski, S.R. 2007. Review: The STAR*D Project results comprehensive of findings. *Current Psychiatry Report*. 9:449-459.
- Weissman, M.M, and Olfson, M. 1995. Depression in women: Implications for health care research. *Science*. 269: 799–801.
- Williams, J.W., Mulrow, C.D., Chiquette, E., Noel, P.H., Augilar, C., and Cornell, J. 2000. Review: A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. *Ann Intern Med*. 132(9):743-56.
- Williams, K., Wheeler, D.M., Silove, N., and Hazell, P. 2010. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). *Cochrane Database Syst Rev* 8: CD004677.
- World Health Organization. 2004. *The Global Burden of Disease*. Geneva. WHO.
- Yang, Y., Walijee, S.M., Jin, J., Zhao, S.P., and Peng, D.Q. 2012. Serum apolipoprotein A-V in patients with coronary artery disease and its association with triglyceride. *J Clin Lipidol*. 6: 462-468.
- Zeugmann, S., Quante, A., Heuser, I., Schwarzer, R., and Anghelescu, I. 2010. Inflammatory biomarkers in 70 depressed in patients with and without the metabolic syndrome. *J Clin Psychiatry*. 71: 1007-1016.
- Zhu, X., and Parks, J.S. 2012. New roles of HDL in inflammation and hematopoiesis. *Annu Rev Nutr*. 32:161-182.

